Based on observations of Julianne Imperato-McGinley of Cornell Medical College, New York presented at a conference on birth defects in 1974 on a peculiar genetic disorder due to type 2 5α-reductase deficiency (5-ARD), oral finasteride was approved in 1992 by the U. S. Food and Drug Administration for treatment of benign prostatic hyperplasia (BPH), and in 1997 for treatment of male pattern baldness (MPB). This article is protected by copyright. All rights reserved.
Experimental dermatology. 2016 Aug 04 [Epub ahead of print]
Ralph M Trüeb
Center for Dermatology and Hair Diseases, University of Zurich, Switzerland.